CD4 and glioblastoma: In a study of 96 patients with high grade gliomas, patients with CD4+ counts under 200 at 2 months after therapeutic initiation were found to have significantly shorter survival than those with higher counts (13.1 vs 19.7 months), highlighting the importance of understanding the effects of treatment in contributing to drug resistance in GBM (Grossman et al., 2011).